<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>5005</id>
    <completedYear/>
    <publishedYear>2024</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>8</pageNumber>
    <edition/>
    <issue>9</issue>
    <volume>29</volume>
    <articleNumber>104128</articleNumber>
    <type>article</type>
    <publisherName>Elsevier</publisherName>
    <publisherPlace>Amsterdam</publisherPlace>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>2024-08-20</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Comparative analysis of FDA approvals by top 20 pharma companies (2014–2023)</title>
    <abstract language="eng">This article addresses the research and development (R&amp;D) productivity challenge of the pharmaceutical industry, focusing on United States Food and Drug Administration (FDA)-related new drug approvals of the top 20 pharmaceutical companies (2014–2023). We evaluated the degree of innovation in new drugs to determine the innovativeness of these leading companies. A key finding of our analysis is the decline in the number of new drugs approved by the FDA for these leading companies over the investigated time period. This trend suggests that some of the leading companies are losing ground in R&amp;D innovation, raising concerns about their ability to sustain competitive advantage, ensure long-term market success, and maintain viable business models.</abstract>
    <parentTitle language="eng">Drug Discovery Today</parentTitle>
    <identifier type="issn">1878-5832</identifier>
    <identifier type="urn">urn:nbn:de:bvb:573-50058</identifier>
    <enrichment key="opus_doi_flag">true</enrichment>
    <enrichment key="opus_import_data">{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:23:06Z","timestamp":1723767786203},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.drudis.2024.104128","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:13:10Z","timestamp":1722888790000},"page":"104128","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative analysis of FDA approvals by top 20 pharma companies (2014\u20132023)"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"http:\/\/orcid.org\/0000-0001-7884-5757","authenticated-orcid":false,"given":"Alexander","family":"Schuhmacher","sequence":"first","affiliation":[]},{"given":"Oliver","family":"Gassmann","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0003-2293-8342","authenticated-orcid":false,"given":"Markus","family":"Hinder","sequence":"additional","affiliation":[]},{"given":"Dominik","family":"Hartl","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2024.104128_b0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3681","article-title":"Diagnosing the decline in pharmaceutical R&amp;D efficiency","volume":"11","author":"Scannell","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0010","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/d41573-020-00059-3","article-title":"Breaking Eroom\u2019s Law","volume":"19","author":"Ringel","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12967-020-02313-z","article-title":"The endless frontier? The recent increase of R&amp;D productivity in pharmaceuticals","volume":"18","author":"Pammolli","year":"2020","journal-title":"J Transl Med"},{"key":"10.1016\/j.drudis.2024.104128_b0020","doi-asserted-by":"crossref","DOI":"10.1038\/d41573-024-00068-6","article-title":"Efficiency, effectiveness and productivity in pharmaceutical R&amp;D","author":"Roland","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0025","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&amp;D productivity: the pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2478\/fman-2013-0004","article-title":"What is innovativeness: literature review","volume":"4","author":"Nasierowski","year":"2012","journal-title":"Found Manag"},{"key":"10.1016\/j.drudis.2024.104128_b0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1108\/14601060210415135","article-title":"Situations for innovation management: towards a contingency model","volume":"5","author":"Drejer","year":"2002","journal-title":"Eur J Innov Manag"},{"key":"10.1016\/j.drudis.2024.104128_b0040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/01.JAC.0000304100.38120.b2","article-title":"Something new every day: defining innovation and innovativeness in drug therapy","volume":"31","author":"Aronson","year":"2008","journal-title":"J Ambul Care Manage"},{"key":"10.1016\/j.drudis.2024.104128_b0045","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1021\/acsmedchemlett.0c00319","article-title":"Structural approach to assessing the innovativeness of new drugs finds accelerating rate of innovation","volume":"11","author":"Wills","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2024.104128_b0050","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/clpt.2013.115","article-title":"Defining, \u201cinnovativeness\u201d in drug development: a systematic review","volume":"94","author":"Kesselheim","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2024.104128_b0055","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1509\/jm.10.0494","article-title":"Firm innovativeness and its performance outcomes: a meta-analytic review and theoretical integration","volume":"76","author":"Rubera","year":"2012","journal-title":"J Mark"},{"key":"10.1016\/j.drudis.2024.104128_b0060","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.indmarman.2003.08.015","article-title":"Innovativeness: its antecedents and impact on business performance","volume":"33","author":"Hult","year":"2004","journal-title":"Ind Mark Manag"},{"key":"10.1016\/j.drudis.2024.104128_b0065","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1509\/jmkg.67.4.82.18687","article-title":"Sources and financial consequences of radical innovation: insights from pharmaceuticals","volume":"67","author":"Sorescu","year":"2003","journal-title":"J Mark"},{"key":"10.1016\/j.drudis.2024.104128_b0070","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrd4336","article-title":"The discovery of first-in-class drugs: origins and evolution","volume":"13","author":"Eder","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0075","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0190","article-title":"Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study","volume":"371","author":"Hwang","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2024.104128_b0080","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2019.20288","article-title":"FDA approval and regulation of pharmaceuticals, 1983\u20132018","volume":"323","author":"Darrow","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2024.104128_b0085","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1021\/acs.jmedchem.0c01516","article-title":"A decade of FDA-approved drugs (2010\u20132019): trends and future directions","volume":"64","author":"Brown","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.104128_b0090","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13023-023-02790-7","article-title":"A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act","volume":"18","author":"Fermaglich","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2024.104128_b0095","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.drudis.2021.12.010","article-title":"Achieving end-to-end success in the clinic: Pfizer\u2019s learnings on R&amp;D productivity","volume":"27","author":"Fernando","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2024.104128_b0100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd.2017.244","article-title":"Impact of a five-dimensional framework on R&amp;D productivity at AstraZeneca","volume":"17","author":"Morgan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrd4454-c1","article-title":"A plan for sustainable funding for US biomedical research","volume":"14","author":"Hensley","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0110","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrd.2016.91","article-title":"Organizational effectiveness: a key to R&amp;D productivity","volume":"15","author":"Tollman","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0115","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.drudis.2012.05.007","article-title":"Drug discovery in pharmaceutical industry: productivity challenges and trends","volume":"17","author":"Khanna","year":"2012","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2024.104128_b0120","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-approved antibody-drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.drudis.2024.104128_b0125","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/d41586-024-01426-5","article-title":"How antibody-drug conjugates aim to take down cancer","volume":"629","author":"Plackett","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.104128_b0130","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.104128_b0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2024.104128_b0140","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","article-title":"RNAi-based drug design: considerations and future directions","volume":"23","author":"Tang","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0145","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nchembio.581","article-title":"Getting pharmaceutical R&amp;D back on target","volume":"7","author":"Bunnage","year":"2011","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2024.104128_b0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0155","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.drudis.2016.08.009","article-title":"The many roles of molecular complexity in drug discovery","volume":"22","author":"M\u00e9ndez-Lucio","year":"2017","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2024.104128_b0160","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.255","article-title":"Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications","volume":"17","author":"Shih","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0165","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrd4725","article-title":"Why is it hard to terminate failing projects in pharmaceutical R&amp;D?","volume":"14","author":"Peck","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0170","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/d41573-023-00048-2","article-title":"First-in-class versus best-in-class: an update for new market dynamics","volume":"22","author":"Spring","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0175","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nrd3405","article-title":"The productivity crisis in pharmaceutical R&amp;D","volume":"10","author":"Pammolli","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0180","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/d41573-021-00018-6","article-title":"The breast cancer drug market","volume":"20","author":"Wilcock","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0185","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/d41573-021-00054-2","article-title":"The oncology market for antibody-drug conjugates","volume":"20","author":"do Pazo","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0195","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrd4650","article-title":"Improving R&amp;D productivity","volume":"14","author":"Smietana","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104128_b0200","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.tips.2018.03.003","article-title":"Orphan drugs and their impact on pharmaceutical development","volume":"39","author":"Attwood","year":"2018","journal-title":"Trends Pharmacol Sci"},{"year":"2012","series-title":"Allies in rare diseases: rare disease facts","author":"Global Genes","key":"10.1016\/j.drudis.2024.104128_b0205"},{"key":"10.1016\/j.drudis.2024.104128_b0210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cts.12500","article-title":"International Rare Diseases Research Consortium (IRDiRC). Future of rare diseases research 2017\u20132027: an IRDiRC perspective","volume":"11","author":"Austin","year":"2018","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.drudis.2024.104128_b0215","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/smj.4250131009","article-title":"Core capabilities and core rigidities: a paradox in managing new product development","volume":"13","author":"Leonard-Barton","year":"1992","journal-title":"Strateg Manag J"},{"key":"10.1016\/j.drudis.2024.104128_b0220","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2307\/2393553","article-title":"Absorptive capacity: a new perspective on learning and innovation","volume":"35","author":"Cohen","year":"1990","journal-title":"Adm Sci q"},{"key":"10.1016\/j.drudis.2024.104128_b0225","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.technovation.2012.01.004","article-title":"The alliance innovation performance of R&amp;D alliances\u2014the absorptive capacity perspective","volume":"32","author":"Lin","year":"2012","journal-title":"Technovation"},{"key":"10.1016\/j.drudis.2024.104128_b0230","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.respol.2008.10.023","article-title":"Absorptive capacity and the search for innovation","volume":"38","author":"Fabrizio","year":"2009","journal-title":"Res Policy"},{"key":"10.1016\/j.drudis.2024.104128_b0235","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/(SICI)1097-0266(199708)18:7&lt;509::AID-SMJ882&gt;3.0.CO;2-Z","article-title":"Dynamic capabilities and strategic management","volume":"18","author":"Teece","year":"1997","journal-title":"Strateg Manag J"},{"key":"10.1016\/j.drudis.2024.104128_b0240","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/1097-0266(200010\/11)21:10\/11&lt;1105::AID-SMJ133&gt;3.0.CO;2-E","article-title":"Dynamic capabilities: what are they?","volume":"21","author":"Eisenhardt","year":"2000","journal-title":"Strateg Manag J"},{"key":"10.1016\/j.drudis.2024.104128_b0245","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/smj.640","article-title":"Explicating dynamic capabilities: the nature and microfoundations of (sustainable) enterprise performance","volume":"28","author":"Teece","year":"2007","journal-title":"Strateg Manag J"},{"year":"2007","series-title":"Dynamic capabilities: understanding strategic change in organizations","author":"Helfat","key":"10.1016\/j.drudis.2024.104128_b0250"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624002538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624002538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T03:33:33Z","timestamp":1723692813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644624002538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1359644624002538"],"URL":"http:\/\/dx.doi.org\/10.1016\/j.drudis.2024.104128","relation":{},"ISSN":["1359-6446"],"issn-type":[{"type":"print","value":"1359-6446"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative analysis of FDA approvals by top 20 pharma companies (2014\u20132023)","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104128"}}</enrichment>
    <enrichment key="local_crossrefDocumentType">journal-article</enrichment>
    <enrichment key="local_crossrefLicence">https://www.elsevier.com/tdm/userlicense/1.0/</enrichment>
    <enrichment key="local_import_origin">crossref</enrichment>
    <enrichment key="local_doiImportPopulated">PersonAuthorFirstName_1,PersonAuthorLastName_1,PersonAuthorIdentifierOrcid_1,PersonAuthorFirstName_2,PersonAuthorLastName_2,PersonAuthorFirstName_3,PersonAuthorLastName_3,PersonAuthorIdentifierOrcid_3,PersonAuthorFirstName_4,PersonAuthorLastName_4,PublisherName,TitleMain_1,Language,TitleParent_1,ArticleNumber,Issue,Volume,CompletedYear,IdentifierIssn,Enrichmentlocal_crossrefLicence</enrichment>
    <enrichment key="opus.source">doi-import</enrichment>
    <enrichment key="THI_relatedIdentifier">https://doi.org/10.1016/j.drudis.2024.104128</enrichment>
    <enrichment key="THI_review">peer-review</enrichment>
    <enrichment key="THI_articleversion">published</enrichment>
    <enrichment key="THI_openaccess">ja</enrichment>
    <licence>Creative Commons BY 4.0</licence>
    <author>
      <first_name>Alexander</first_name>
      <last_name>Schuhmacher</last_name>
    </author>
    <author>
      <first_name>Oliver</first_name>
      <last_name>Gassmann</last_name>
    </author>
    <author>
      <first_name>Markus</first_name>
      <last_name>Hinder</last_name>
    </author>
    <author>
      <first_name>Dominik</first_name>
      <last_name>Hartl</last_name>
    </author>
    <collection role="institutes" number="15986">THI Business School</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="persons" number="44756">Schuhmacher, Alexander</collection>
    <thesisPublisher>Technische Hochschule Ingolstadt</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-haw/files/5005/1-s2.0-S1359644624002538-main.pdf</file>
  </doc>
</export-example>
